Is gefitinib a competitive inhibitor?

Gefitinib is known to competitively inhibit CYP2D6 activity.

What causes TKI resistance?

Most often, resistance to tyrosine kinase inhibitors (TKI) used to treat chronic myeloid leukemia (CML) is caused by changes (mutations) in the part of the BCR-ABL gene that makes the BCR-ABL protein. Mutations change the shape of the BCR-ABL protein so that certain TKIs can no longer bind to it effectively.

Is erlotinib a competitive inhibitor?

Gefitinib and erlotinib are the first EGFR TKIs approved for treatment of EGFR-mutation positive NSCLC (1). They are effective against L858R and exon 19 deletion. Both are reversible competitive inhibitors of ATP for the tyrosine kinase domain of EGFR.

Is gefitinib a TKI?

Background. Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC).

What is EGFR TKI?

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Progression inevitably happens after 10–14 months of first- or second-generation EGFR TKIs treatment for acquired resistance.

How do EGFR inhibitors work?

They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. They block the activity of a protein called “EGFR” and thus prevent unregulated cell division.

What is T315I mutation?

T315I is a common mutation that accounts for ∼20% clinical resistance to TKIs. We report the first case of a patient with T315I mutated myeloid sarcoma that occurred after complete cytogenetic response with dasatinib of a chronic phase CML. The patient was successfully treated with induction chemotherapy and ponatinib.

What does BCR ABL stand for?

Background: A specific chromosomal abnormality, the Philadelphia chromosome (BCR-ABL fusion), is present in all patients with chronic myeloid leukemia (CML).

What is difference between erlotinib and gefitinib?

Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment.